Nintedanib in IPF: Post hoc Analysis of the Italian FIBRONET Observational Study – Abstract – Respiration

Harari S.^a,b · Pesci A.^c · Albera C.^d · Poletti V.^e,f · Amici C.^g · Crespi G.^h · Campolo B.^h · Vancheri C.ⁱ · on behalf of the FIBRONET study group

Author affiliations

^aDepartment of Clinical Sciences and Community Health, University of Milan, Milan, Italy
^bU.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria, Ospedale San Giuseppe, IRCCS MultiMedica, Milan, Italy
^cDepartment of Medicine, Respiratory Unit, University of Milano-Bicocca, ASST Monza, Monza, Italy
^dSC Pneumologia U, A.O.U. Città Della Scienza e della Salute (Molinette), University of Torino, Turin, Italy
^eDepartment of Diseases of the Thorax, Ospedale GB Morgagni, Forlì, Italy
^fDepartment of Respiratory Diseases & Allergy, Aarhus University Hospital, Aarhus, Denmark
^gMediNeos Observational Research, Modena, Italy
^hBoehringer Ingelheim, Milan, Italy
ⁱRegional Referral Centre for Rare Lung Diseases, University-Hospital “Policlinico G. Rodolico”, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy

Corresponding Author